Objective: Current data are limited on the course of type 1 diabetes (T1D) in children and adolescents through the first few years of diabetes. The Pediatric Diabetes Consortium T1D new onset (NeOn) Study was undertaken to prospectively assess natural history and clinical outcomes in children treated at 7 US diabetes centers from the time of diagnosis. This paper describes clinical outcomes in the T1D NeOn cohort during the first 3 years postdiagnosis.
| INTRODUCTION
It has long been recognized that optimal metabolic control is much easier to achieve during the partial remission (or honeymoon) period in youth with new-onset type 1 diabetes (T1D) than later in the course of the disease. Moreover, the Diabetes Control and Complications Trial (DCCT) demonstrated that intensive treatment of T1D could slow the loss of residual β-cell function, resulting in lower glycated hemoglobin (HbA1c) levels and a reduced risk of severe hypoglycemia. 1 The recent DirecNet/TrialNet Metabolic Control Study 2, 3 and the European Pediatric Onset Study 4 indicate that the highest C-peptide values and lowest HbA1c levels are observed in youth with newly diagnosed T1D during the first 6 months of treatment, whereas C-peptide levels begin to decline and HbA1c levels increase over the subsequent 6 months. [2] [3] [4] [5] [6] Outside of the relatively small numbers of participants enrolled in clinical trials of early use of insulin pumps and continuous glucose monitors, the time course, and consequences of loss of residual β-cell function in youth with new onset T1D in clinical practice settings has not been well established. A clear understanding of the waning of the honeymoon phase of T1D in children and adolescents would facilitate the design of clinical trials of new therapies aimed at preserving residual β-cell function, as well as enhancing vigilance in diabetes management during this critical phase of transition. 7 In order to fill gaps in knowledge regarding the natural history of the honeymoon phase of T1D in children and adolescents, the Pediatric Diabetes Consortium (PDC) enrolled pediatric patients who had been newly diagnosed with T1D into the New Onset (NeOn) Study. 5 Clinical outcomes in the NeOn cohort during the first year of treatment were similar to those in recent clinical trials, in that the lowest HbA1c levels were observed between 3 and 6 months postdiagnosis, with a progressive rise in HbA1c values at 9 and 12 months. 5 In this paper, we describe the results of follow-up evaluations in the PDC T1D NeOn Study cohort after the first year following diagnosis through up to 3 years of follow up.
2 | METHODS
| Patients
The 
| RESULTS
The mean age of the cohort at diagnosis was 9.2 years (range: 0.7-18.8 years); 49% were female; 65% were non-Hispanic White, 21%
were Hispanic, and 8% were non-Hispanic Black ( Table 1 ). The majority of participants had health insurance, parents with a college degree or above, and a family income greater than $50,000. A comparison of a Participant/parent was asked at the visit whether an event had occurred in the previous 12 months.
b N varies due to missing data at the particular time point.
c DKA events at diagnosis were excluded.
* Changes from the prior column.
baseline factors in 3-year completers vs non-completers is shown in Table S1 , Supporting Information, and clinical outcome measures among 3-year completers are reported in Table S2 .
| Glycemic control of T1D
Nadir mean HbA1c (AESD) was 7. (Table 2 and Figure 1 ). The highest HbA1c levels at 36 months were seen in adolescents (Table 2) . A total of 61% of participants achieved target HbA1c levels <7.5% (58 mmol/mol) at 3 and 6 months but this fell to only 30% by 36 months. HbA1c levels were significantly corre- 
| Diabetes management
An insulin pump was being used by 46% of participants at 24 months and 48% at 36 months. Only 2% to 4% of participants reported using a continuous glucose monitor between 6 and 36 months. The median self-reported number of self-monitored blood glucose (SMBG) tests per day remained consistent at 5/d through 36 months (Table 2 ).
There was a significant association between HbA1c and the daily number of SMBG tests with a correlation that increased from 12 months to 36 months (r = −.27, −.24, −.33 for 12, 24, and 36 months respectively, all P-values < .001).
| Insulin dose adjusted HbA1c
As shown in Table 2 , there also was a progressive increase in IDAA1c that reflected the increases in HbA1c values and total daily insulin doses over the course of the study. Consequently, the percentage of participants who were in partial remission, as indicated by IDAA1c values ≤9.0, fell from 49% at 3 months to 23% at 12 months and to only 7% at 36 months, respectively. The rate of decline in C-peptide estimated by the IDAA1c was lower in younger participants.
| Body mass index
The median (interquartile range) BMI percentile was 50% (14-78%) at the time of diagnosis, increased to 69% (44%-88%) at 6 months, and then remained relatively constant throughout the first 3 years of T1D
( Figure 3 ). BMI percentile was inversely associated with HbA1c (P < .001) after adjusting for visit time.
| Severe hypoglycemia and DKA
During the first year of T1D, SH episodes were reported by 2% of participants. By 24 and 36 months, the percentages of participants with SH episodes in the prior 12 months were 3% and 4%, respectively. The percentage of participants who reported more than 1 episode of SH within the prior 12 months was only 1% at 36 months.
DKA occurred in 1% of participants during the first year of T1D, not including episodes at presentation. By 24 and 36 months, the percentages of participants with DKA in the prior 12 months increased considerably to 6% and 6% ( with a DKA event also had significantly higher IDAA1c than those without a DKA event after adjusting for visit time (P = .002). There was no significant difference in either HbA1c or IDAA1c levels between those participants with a SH event and those without a SH event after adjusting for visits (P = .18 and .64, respectively).
| Comorbidities diagnosed after initial screening evaluation at diagnosis
As shown in Table 3 , the cumulative rate for diagnosis of thyroid disease slightly increased from 2% during the first year after diagnosis to 3% after 3 years. While only <1% of participants had been diagnosed with psychiatric disorders and 2% had been diagnosed with celiac disease during the first year of diabetes, the cumulative event rate of psychiatric disorders and celiac disease increased to 2% and 5%, respectively after 3 years of T1D duration.
| DISCUSSION
An important finding of this study is that the rise in HbA1c levels, increases in total daily insulin doses and waning of the partial remission period that were observed between 6 and 12 months after the diagnosis of T1D in this cohort 5 HbA1c levels were higher in the NeOn Study cohort at each time point. These differences may be due to the difference in the frequency and intensity of contact with participants in clinical trials vs patients in clinical practice, but could also be due to differences in patients who participate in clinical trials vs those who do not. It is noteworthy that patients and caregivers responded to the increasing challenges in managing their diabetes by maintaining a high frequency of blood glucose monitoring and increasing use of insulin pumps over time.
While C-peptide responses to mixed meal tolerance tests were not measured in the NeOn Study, the IDAA1C developed and validated by Mortensen et al, was used as a surrogate measure of residual β-cell function. 8 Those investigators showed that an IDAA1C value ≤9.0 predicts peak meal-stimulated C-peptide levels that are almost always >300 pmol/L. Similar C-peptide responses can be seen in youth with T1D with IDAA1C values between 9.0 and 10.0, albeit less frequently. Although there is data supporting the use of IDAA1c, the IDAA1c has some limitations. The data were derived from a non-US population with a different genetic background. The stimulated Cpeptide cut-off level as a measure of residual β-cell function was even higher than the cut-off level that was used to define absolute insulin deficiency in the DCCT cohort (C-peptide <200 pmol/L) despite the fact that, unlike the DCCT patient population, subjects younger than 13 years were enrolled into the study by Mortensen. Hence, the IDAA1c might not be applicable to assess the β-cell reserve for younger patients who tend to have lower C-peptide levels as compared with older people with new onset T1D. Moreover, the DPV partial remission analysis demonstrated younger children are significantly less likely to experience partial remission. 10 The data points on the suggests that future β-cell preservation studies may have to be extended to 24-36 months in order to detect differences in C-peptide responses between experimental and control groups.
It was somewhat surprising that the reported frequency of SH episodes did not increase with waning of the partial remission phase during the first 3 years of diabetes treatment. One possible explanation is that the IDAA1c might not be a sensitive measure to determine the risk for severe hypoglycemia in this patient population. Unlike SH, the number of episodes of DKA did rise in parallel to the rise in HbA1c levels, a finding similar to that in pediatric patients with longer diabetes duration enrolled in the T1D Exchange Clinic Registry.
12
T1D Exchange Registry data indicate that youth with T1D have not been spared from the epidemic of obesity that afflicts so many non-diabetic children. 13 Thus, the initial increase in BMI to >60th percentile at 6 months is likely due to the regain of weight lost prior to the diagnosis of diabetes, whereas, the lack of any substantial change in BMI after 6 months is evidence against a major effect of insulin treatment itself.
It is not uncommon for associated autoimmune diseases to develop after the diagnosis of T1D, and this explains the increasing prevalence of thyroid and celiac disease over time. The increasing prevalence of psychiatric disorders probably represents the increasing age of the cohort as participants entered adolescence, increased awareness of mental health issues 14 as well as the longer duration of the disease.
There are a few limitations of the PDC NeOn Study. The study was not designed as a population-based study, because all the participants enrolled into the study were being followed in academic pediatrics diabetes centers within 3 months of diagnosis. While this factor raises a concern about representativeness of our findings, the majority of pediatric patients with T1D in the United
States are managed by pediatric diabetologists as common practice, unlike the adult patient population whose care is often shared by specialists and primary care givers. 15 Maximum amount of possible follow up was incomplete for 29% of the cohort; however, baseline characteristics appeared quite similar between those with complete vs incomplete follow up, suggesting that this is not a source of bias.
The findings of the NeOn Study underscore the importance of maintaining a commitment by patients and parents of children with T1D to intensive insulin therapy during the transition period out of the partial remission phase in order to keep HbA1c levels within the target range. Unfortunately, only about 30% of participants were able achieve this goal after the first 2 years of T1D despite their highmedian income and well-educated background. The percentage of pediatric patients who are within target glycemic range has been reported to be even lower, based on a recently published database study. 16 Nevertheless, improvements in accuracy and ease of use of continuous glucose monitor devices and the introduction of integrated sensor-augmented pump systems provide new and relatively untapped opportunities for achieving optimal glycemic control in a larger proportion of youth with T1D, 17 including those recently diagnosed. As the DCCT has shown, getting a larger proportion of patients to target HbA1c levels as early in the course of the disease as possible will have long-lasting benefits in reducing the risk of future vascular complications. 
